AVROBIO, Inc. (AVRO)
|52 Week Range||0.57-1.93|
|1y Target Est||-|
|DCF Unlevered||AVRO DCF ->|
|DCF Levered||AVRO LDCF ->|
|Debt / Equity||1.70%||Neutral|
Upgrades & Downgrades
Latest AVRO news
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
8 November 2023
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
23 October 2023
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
6 October 2023
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
12 August 2023
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its va...
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
13 July 2023
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
How to Handle Penny Stocks Volatility in 2023
23 May 2023
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their in...
Why Is AVROBIO (AVRO) Stock Up 83% Today?
22 May 2023
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to...
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
18 May 2022
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different ...
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
17 May 2022
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cy...
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
9 February 2022
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using...